Amarin Corp Plcuk (AMRN) Common Equity (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Common Equity of $443.6 million for Q2 2026, down 4.58% year-over-year from $464.9 million in Q2 2025, and down 1.29% quarter-over-quarter from $449.4 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Common Equity (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Common Equity for 17 consecutive years, with $443.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 4.58% year-over-year to $443.6 million; the TTM figure through Jun 2026 stood at $443.6 million (down 4.58% YoY), while the FY2025 annual figure was $459.3 million, down 5.53% from the prior year.
- Common Equity fell to $443.6 million in Q2 2026 per AMRN's latest filing, from $449.4 million in the prior quarter.
- Across five years, Common Equity topped out at $641.1 million in Q1 2022 and bottomed at $443.6 million in Q2 2026.
- Historically, Common Equity has averaged $529.4 million across 5 years, with a median of $548.9 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity rose 1.02% — and 2025, when it retreated 15.76%.
- Amarin Corp Plc\Uk's Common Equity stood at $595.3 million in 2022, then fell by 7.26% to $552.1 million in 2023, then decreased by 11.94% to $486.2 million in 2024, then retreated by 5.53% to $459.3 million in 2025, then decreased by 3.41% to $443.6 million in 2026.
- Business Quant data shows AMRN's Common Equity at $443.6 million in Q2 2026, $449.4 million in Q1 2026, and $459.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.02 Bn | 463.46 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 379.06 Bn | 371.92 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 302.95 Bn | 295.26 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 236.97 Bn | 222.98 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 182.78 Bn | 179.60 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 161.51 Bn | 149.81 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.54 Bn | 101.37 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Amarin Corp Plcuk | 5.85 Bn | 5.53 Bn | 14.99 Mn | 443.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 443.62 Mn |
| Mar 31, 2026 | 449.41 Mn |
| Dec 31, 2025 | 459.28 Mn |
| Sep 30, 2025 | 458.89 Mn |
| Jun 30, 2025 | 464.92 Mn |
| Mar 31, 2025 | 473.69 Mn |
| Dec 31, 2024 | 486.18 Mn |
| Sep 30, 2024 | 531.38 Mn |
| Jun 30, 2024 | 551.88 Mn |
| Mar 31, 2024 | 545.94 Mn |
| Dec 31, 2023 | 552.10 Mn |
| Sep 30, 2023 | 553.15 Mn |
| Jun 30, 2023 | 569.13 Mn |
| Mar 31, 2023 | 584.79 Mn |
| Dec 31, 2022 | 595.33 Mn |
| Sep 30, 2022 | 587.83 Mn |
| Jun 30, 2022 | 580.04 Mn |
| Mar 31, 2022 | 641.11 Mn |
| Dec 31, 2021 | 667.10 Mn |
| Sep 30, 2021 | 642.50 Mn |